Novartis scemblix aximini instructions for use detailed

Asiminib (Scemblix) is an innovative targeted therapy drug developed by Novartis. Its active substance is a tyrosine kinase inhibitor (TKI). In the treatment of Ph+ CML, aximini can specifically block BCR-ABL1 tyrosine kinase, thereby effectively inhibiting the division and growth of abnormal white blood cells and controlling the progression of the disease. Clinical trials have proven that this drug has significant efficacy and safety. In order to allow patients to better understand and use this drug, this article will introduce the instructions for use of Aceminid in detail.

Aximini is a prescription drug, so be sure to consult your doctor before taking it to make sure it is suitable for your condition. The drug is indicated for adult patients with chronic phase Philadelphia chromosome-positive CML who have previously received two or more tyrosine kinase inhibitors (TKIs); adult patients with chronic phase Philadelphia chromosome-positive CML with T315I mutation; newly diagnosed chronic phase Philadelphia chromosome-positive CML.

When using aceminib, patients need to strictly follow the recommended dosage regimen. For patients with newly diagnosed or previously treated Ph+ CML-CP, it is recommended to take 80 mg orally once daily at approximately the same time each day, or choose to take 40 mg orally twice daily approximately 12 hours apart. Importantly, Asiminib should be taken orally without food, avoiding food for 2 hours before and 1 hour before and after taking it.

For Ph+ CML-CP patients withT315I mutation, the recommended dose of aximinib has been adjusted to 200 mg orally twice a day, with an interval of about 12 hours between doses. Likewise, the medication should be taken on an empty stomach and follow the dietary taboos mentioned above.

If it is a once-daily regimen, after the missed dose exceeds approximately 12 hours, the patient needs to skip the dose and take the next dose as planned; and under the twice-daily regimen, if the missed dose exceeds 6 hours, the patient also needs to skip the dose and continue to take the next dose as originally planned.

When taking Asiminib, be sure to swallow the tablets whole and do not break, crush, or chew them. In addition, patients should not change the dosage or discontinue treatment unless otherwise instructed by the attending physician. This is to avoid negatively affecting the effectiveness of the treatment or causing unnecessary risks.

Aceminid may interact with many other medications, so patients should inform their doctor of all medications they are currently taking, including new ones they start or stop taking. The doctor will evaluate the patient's specific situation to formulate an optimal medication plan.

In clinical observations, common adverse reactions include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain and diarrhea. Patients should communicate with their doctor promptly when experiencing these symptoms to receive appropriate management and support.

In summary, Asiminib is an effective treatment for Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) patients provide new possibilities. Patients must strictly follow medical recommendations when using it to ensure the safety and efficacy of the drug.

References:

https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix

https://www.drugs.com/pro/scemblix.html